Ampliphi Biosciences Stock 770% Upside From Current Price

Ampliphi Biosciences stock has rising large players volume after the company released incredible phase 1 trial results from their phage therapy cure for antibiotic resistant superbugs.

Ampliphi Biosciences Stock

Summary

  • Antibiotic resistant superbugs are on the rise killing more than 23,000 Americans each year.
  • By 2050, 10 million people will die each year from infections that are curable today like ear and paper-cut infections.
  • Phage therapy can kill superbugs but still needs lots of work and FDA approval.
  • Ampliphi Biosciences is conducting several phage therapy clinical trials in 2018.
  • Large players volume is rising in Ampliphi Biosciences stock after incredible clinical trial data was released in early January 2018.
  • Author: Lance Jepsen

    For ethical purposes, I try not to hold any position in any stock I profile on GuerillaStockTrading.com unless specifically stated in the article. Owner of GuerillaStockTrading.com. Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade.

    Leave a Reply